Survivin expression in ganglioglioma
- 58 Downloads
Gangliogliomas are unusual central nervous system (CNS) neoplasms occurring mainly in children and young adults and inducing chronic pharmacoresistant epilepsy. These are usually well differentiated neuroepithelial tumors composed of neurons in association with neoplastic glial cells. Gangliogliomas present with favorable outcome. However, some may recur and/or progress to anaplasia and be associated with a dismal prognosis. Since histopathological features do not consistently correlate with clinical outcome, reliable prognostic factors have yet to be defined in gangliogliomas. Survivin is an anti-apoptotic protein whose expression has been found to be of prognostic significance in many human cancers, including gliomas. The objective of this study was to assess survivin expression using immunohistochemistry in 15 gangliogliomas. Ten lesions were low-grade neoplasms whereas 5 were high-grade tumors. Survivin expression appeared restricted to the neoplastic glial component and was detected in 6/15 gangliogliomas. Two additional tumors expressed survivin upon relapse. Half survivin expressing lesions displayed less than 1% immunoreactive cells. Survivin expression in more than 5% neoplastic glial cells was detected only in malignant and/or recurrent gangliogliomas. Extended lifespan in survivin expressing cells might enhance aggressive behavior in these tumors through accumulation of mutations, thereby allowing progression to malignant phenotypes. Survivin expression may carry a negative prognostic value in gangliogliomas.
Keywordsapoptosis brain tumor central nervous system ganglioglioma glioneuronal tumor immunohistochemistry prognosis survivin
Unable to display preview. Download preview PDF.
- 1.Lantos PL, Louis DN, Rosenblum MK, Kleihues P: Tumours of the nervous system In: Graham DI, Lantos PL, (eds) Greenfield’s Neuropathology. Arnold, London 2002, pp. 767–980Google Scholar
- 2.Nelson JS, Bruner JM, Wiestler OD, Vandenberg SR, 2000 Ganglioglioma and gangliocytoma In: Kleihues P, Cavenee WK, (eds) Pathology and Genetics of Tumours of the Nervous System. World Health Organization Classification of TumoursIARC, Lyon, 96–98Google Scholar
- 27.Fangusaro JR, Jiang Y, Holloway MP, Caldas H, Singh V, Boué DR, Hayes J, Altura RA, 2005 Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcomeBr J Cancer 1–7Google Scholar
- 30.Caldas H, Jiang Y, Holloway MP, Fangusaro J, Mahotka C, Altura RA, Conway EM, 2005 Survivin splice variants regulate the balance between proliferation and cell death. Oncogene 1–14Google Scholar
- 39.Li F, 2004 Role of survivin and its slice variants in tumorigenesisBr J Cancer 1–5Google Scholar
- 40.Hassounah M, Lach B, Allam A, Al-Khalaf H, Siddiqui Y, Pangue-Cruz N, Al-Omeir A, Al-Ahdal MN, Aboussekhra A, 2005 Benign tumors from the human nervous system express high levels of survivin and are resistant to spontaneous and radiation-induced apoptosisJ Neurooncol 72: 203–208PubMedCrossRefGoogle Scholar